Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bentley announces cash purchase price adjustment
Bentley stockholders will receive from Teva a final per-share purchase price of approximately $14.82 in cash in exchange for their Bentley common stock if the merger agreement is
Bentley stockholders will receive from Teva a final per-share purchase price of approximately $14.82 in cash in exchange for their Bentley common stock if the merger agreement is
The $3 million grant will fund efforts to further develop Antigen Discovery’s (ADI) protein microarray based serodiagnostic platform for applications in biodefense and emerging infectious diseases. ADI will
Senesco has previously reported positive preclinical in vivo results using its combination siRNA and plasmid against subcutaneous multiple myeloma tumors in immunodeficient mice. Bruce Galton, president and CEO
The company currently markets Granisetron in 0.1mg/ml, 1ml single dose vials and will commence distributing the 1mg/ml, 1ml single dose, and 1mg/ml, 4ml multiple dose vials immediately. All
This follows the resignation of William Pinon as the company’s president and CEO and as a member of the board of directors as of the same date. Mr
Senesco has previously reported positive preclinical in vivo results using its combination siRNA and plasmid delivered with ‘in vivo-jetPEI’ against subcutaneous multiple myeloma tumors in immunodeficient mice. Bruce
Under the terms of the five-year agreement, Akorn will be responsible for the manufacturing and supply of the two injectable products. Expected launch for both products is anticipated
Pursuant to the agreement, Regeneron will make an up-front payment to Cellectis in the amount of $12.45 million. In addition, Regeneron will pay Cellectis a low single-digit royalty
The trial includes four groups of 10 subjects each to assess the safety of escalating doses of RGN-352 injected into the blood stream. A final analysis and report
The renewal includes a rate increase for the period April 1, 2008 through June 30, 2008, as well as a rate increase for the period July 1, 2008